Starting Strength is the bestselling book on the most fundamental and effective approach to strength training ever written. Mark Rippetoe hosts Starting Strength Radio where he discusses topics of interest, primarily to him, but perhaps also to you.
…
continue reading
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S5 Ep14: Goodbye 2022—The Top 10 Biosimilars Stories of the Year
MP3•Episode home
Manage episode 353239881 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Top 10 stories of the year:
10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar
9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA
8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology
6. Report: Biosimilar Competition in Europe
5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options
- For the whole series, click here.
4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira
3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab
2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid
10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar
9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA
8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology
6. Report: Biosimilar Competition in Europe
5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options
- For the whole series, click here.
4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira
3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab
2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid
Top 5 podcast episodes of the year:
5. How Health Policy Can Impact Adoption for Adalimumab Biosimilars
4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar
3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars
2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market
1. What Will Year 1 Look Like for Adalimumab Biosimilars?
4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar
3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars
2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market
1. What Will Year 1 Look Like for Adalimumab Biosimilars?
157 episodes
MP3•Episode home
Manage episode 353239881 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Top 10 stories of the year:
10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar
9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA
8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology
6. Report: Biosimilar Competition in Europe
5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options
- For the whole series, click here.
4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira
3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab
2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid
10. FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar
9. Contributor: No Animal Testing of Biosimilars—US Congress Begins Amendment to BPCIA
8. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
7. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology
6. Report: Biosimilar Competition in Europe
5. Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options
- For the whole series, click here.
4. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira
3. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab
2. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
1. Teva Announces US Launch of Lenalidomide, Generic of Revlimid
Top 5 podcast episodes of the year:
5. How Health Policy Can Impact Adoption for Adalimumab Biosimilars
4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar
3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars
2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market
1. What Will Year 1 Look Like for Adalimumab Biosimilars?
4. New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar
3. What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars
2. How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market
1. What Will Year 1 Look Like for Adalimumab Biosimilars?
157 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.